Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Announces Data Demonstrating Potential of Protein Marker as Ovarian Cancer Prognostic


Australian protein biomarker firm HealthLinx said this week it has completed a validation study assessing the potential prognostic value of an undisclosed protein biomarker for ovarian cancer.

According to the company, the marker was shown to be highly expressed in ovarian carcinoma tissue in patients with better clinical outcomes, with high expression associated with a 22 percent relapse rate compared to a 78 percent relapse rate in patients showing low expression.

Conducted at the Department of Anatomical Pathology at the Mater Health Services, Brisbane, the study used tissue microarrays from 200 patients comprising benign, malignant, and control samples. Expression of the marker was correlated with disease-free survival for up to 80 months.

The study "effectively positions the company to provide a vertical solution to the diagnosis of ovarian cancer with our OvPlex test and now potentially provide clinicians with an additional prognostic indicator with this novel biomarker," HealthLinx managing director Nick Gatsios said in a statement.

The company said it plans to disclose the marker and the research findings in a peer-reviewed publication "pending submission of new patent applications to cover the novel findings."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.